Early Development Programs
Tavanta is progressing early development programs in a number of rare diseases including Cystic Fibrosis.
TAVT-135 is an inhaled peptide-small molecule conjugate being explored as a treatment for cystic fibrosis. TAVT-135 has a unique mechanism of action as an artificial chloride ion transporter across cell membranes. The restoration of chloride ion levels in the airways prevents mucus thickening and accumulation, and subsequently slows the progressive deterioration of lung function. Initial in-vitro and ex-vivo experiments have successfully demonstrated gradient driven transport of chloride ions without any cell toxicity.